 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reports financial results for the first quarter ended on march 31, 2016. 
 we report net loss of $11 million or $0.24 basic net loss per share as compared to net loss of $10 million or $0.23 basic net loss per share for the first quarter of 2015.    during the first quarter of 2016, we made significant progress in the development of our product candidates ARX-04, sufentanil sublingual tablet, 30 micrograms, and Zalviso, sufentanil sublingual system, including the initiation of two new clinical studies.    in the first study, we enrolled 40 patients to present to the emergency room with moderate to severe acute pain from trauma or injury.    
 the primary endpoint was the time-weighted summed pain intensity difference to baseline over one hour or the time - weighted summed pain intensity difference to baseline over 12 hours or the time - weighted summed pain intensity difference over 12 hours or the time - weighted summed summed pain intensity difference to baseline over 12 hours.    in the second study, we initiated an open-label clinical study,